Sonnet BioTherapeutics Holdings, Inc. announced that the SB221 study of SON-1010 (recombinant human Interleukin-12 linked to Sonnet's fully-human albumin binding domain or IL12-FHAB) dosed in combination with atezolizumab (Tecentriq) will be presented as a 'Trial in Progress' poster at ASCO 2024. Study SB221 (NCT05756907) is a Phase 1b/2a multicenter, dose-escalation, and proof-of-concept clinical study to assess the safety, tolerability, PK, PD, and efficacy of SON-1010 administered SC, either alone or in combination with a fixed dose of atezolizumab given IV. The work will be presented in a poster session at the upcoming American Society of Clinical Oncology Annual Meeting 2024, to be held May 31 to June 4 in Chicago, Illinois.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9375 USD | -1.15% | -4.34% | -46.12% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.12% | 2.92M | |
+55.32% | 815B | |
+44.05% | 641B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+13.31% | 218B | |
+8.48% | 168B | |
-2.81% | 159B |
- Stock Market
- Equities
- SONN Stock
- News Sonnet BioTherapeutics Holdings, Inc.
- Sonnet Biotherapeutics Holdings, Inc. to Present SB221 as A Trial in Progress At the Asco 2024 Annual Meeting